CYTK Q4 2017 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$18,000-100.1% YoY

Gross Profit

-$26M145938.9% margin

Operating Income

-$37M202927.8% margin

Net Income

-$40M224916.7% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

-100.3%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$295M

Total Liabilities

$185M

Stockholders' Equity

$110M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$18,000	$33M	-100.1%
Gross Profit	-$26M	$10M	-366.4%
Operating Income	-$37M	$8M	-575.1%
Net Income	-$40M	$7M	-665.7%

Revenue Segments

Cardiac Muscle Activator Of Omecamtiv Mecarbil

$1M100%